-
-
In this issue: Apixaban approval; new dental clinical practice guideline; apixaban for VTE; aspirin resistance; tamoxifen treatment; and FDA actions.
-
Handoffs have been extensively examined as a potential source of communication failure. Such studies typically focus on how to best share details of care when patient responsibility is transferred from one clinical care team to another.
-
-
-
More than 95% of shoulder dislocations are anterior in location.
Pre- and post-reduction radiographs are not required in patients with chronic recurrent dislocations who have dislocations with minor or no trauma.
Leverage reduction techniques may be able to reduce the dislocation without the need for opiates or sedatives.
Post-reduction immobilization is primarily done for patient comfort, not to reduce the risk of recurrent dislocation.
-
Optimism is associated with a significantly healthier lipid profile than is present in less optimistic persons, possibly due to healthier behaviors and lower body mass indices, which are found with increased frequency in optimistic individuals.
-
A new product has been approved for the urgent reversal of warfarin or other vitamin K antagonists anticoagulation in the setting of acute bleeding. This human plasma-derived product contains vitamin K-dependent coagulation Factors II, VII, IX, and X as well as antithrombotic Protein C and Protein S. It is heat-treated and viral filtered. Prothrombin complex concentrate (PCC) is manufactured by CSL Behring GmbH in Germany and marketed by CSL Behring LLC as Kcentra. The product has been licensed in Germany since 1996.
-
-
